<DOC>
	<DOCNO>NCT01238770</DOCNO>
	<brief_summary>The current trial shall clarify potential multitarget antiangiogenic tyrosinkinase inhibitor GW 786034 ( pazopanib ) combination oral cyclophosphamide salvage treatment patient recurrent , pretreated ovarian cancer .</brief_summary>
	<brief_title>Phase I/II Study Pazopanib Cyclophosphamide Patients With Platinum-resistant Recurrent Ovarian Cancer</brief_title>
	<detailed_description>This study prospective open-label , non-randomized multicenter phase I/II trial order determine overall response rate patient platinum-resistant refractory recurrent , pretreated epithelial ovarian cancer . In order assure adequate toxicity assessment , phase-I-trial proponed . Phase II perform MTD .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Written inform consent 2 . Female subject â‰¥18 year age 3 . Histologically cytologically confirm diagnosis : epithelial ovarian cancer platinum resistant platinum refractory , cancer fallopian tube , peritoneal cancer 4 . Patients must fail available standard chemotherapy regimen 5 . Prior treatment least 2 chemotherapy regimen advance tumor set 6 . Performance status ECOG 0 2 7 . Adequate contraception 8 . Adequate organ function 9 . Measurable disease accord RECIST criterion . 10 . Able swallow retain oral medication . 11 . Life expectancy least 12 week . 1 . Any second malignancy within last 5 year , exception basal cell squamous cell skin cancer situ carcinoma cervix uteri 2 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . 3 . Clinically significant gastrointestinal abnormality might interfere oral dose 4 . Any unstable serious concurrent condition ( e.g. , active infection require systemic therapy ) . 5 . Prolongation correct QT interval ( QTc ) &gt; 480 msec . 6 . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Symptomatic peripheral vascular disease Coronary artery bypass graft surgery Class II , III IV congestive heart failure define New York Heart Association ( NYHA ) History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month 7 . Macroscopic hematuria 8 . Hemoptysis clinically relevant within 4 week first dose study drug 9 . Evidence active bleeding bleed diathesis 10 . Known endobronchial lesion involvement large pulmonary vessel tumor 11 . Prior major surgery trauma within 14 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer . 12 . Chemotherapy radiation therapy within 2 week prior first dose study drug . 13 . Biological therapy , hormonal therapy treatment investigational agent within 28 day 5 halflives 14 . Prior antiangiogenic therapy . 15 . Is unable unwilling discontinue predefined prohibited medication list protocol 14 day five halflives drug ( whichever longer ) prior Visit 1 duration study 16 . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity . 17 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib 18 . Psychological , familial , sociological , geographical condition permit compliance protocol . 19 . Pregnancy 20 . More 3 different chemotherapy regimen advance tumor set 21 . Uncontrolled hypertension 22 . History ischemic event ( stroke , myocardial infarction , unstable angina , TIA , symptomatic peripheral vascular disease ) 23 . History clinical evidence thromboembolic event 24 . History haemoptysis , cerebral , clinically significant gastrointestinal haemorrhage past 6 month 25 . Active bleed 26 . Signs/Suspicion intestinal obstruction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
</DOC>